Skip to content

Mindfulness-Based Cognitive Therapy for Perinatal Women with Depression or Bipolar Spectrum Disorder.

David J. Miklowitz, Randye J Semple, Monika Hauser, Dana Elkun, Marc J. Weintraub, Sona Dimidjian

Cognitive Therapy and Research October 2015 DOI: 10.1007/s10608-015-9681-9 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Uncontrolled feasibility study Peer reviewed
Sample size 39
Population Perinatal women with a lifetime history of major depressive disorder or bipolar spectrum disorder, most with subthreshold mood symptoms; participants were pregnant, planning pregnancy, or up to 1-year postpartum
Interventions Mindfulness-based cognitive therapy (MBCT) meditation yoga mood regulation strategies
Duration 8-week program with follow-up at post-treatment and 1 and 6 months post-treatment
Topics Depression Meditation
Keywords Acceptability Feasibility Mania Postpartum Pregnancy
Key points Participants with major depressive disorder reported average improvements in depression from pre- to post-treatment, while no mood improvement was observed in the bipolar spectrum disorder group. Of 32 completers, 7 (21.9%) had a major depressive episode during 6-month follow-up. The authors suggest MBCT may be an important component of care for perinatal women with histories of major depression, but its applicability to those with bipolar spectrum disorder is unclear.

Abstract

The perinatal period is a high-risk time for mood deterioration among women vulnerable to depression. This study examined feasibility, acceptability, and improvement associated with mindfulness-based cognitive therapy (MBCT) in perinatal women with major depressive disorder (MDD) or bipolar spectrum disorder (BSD). Following a diagnostic evaluation, 39 perinatal women with a lifetime history of MDD (n = 27) or BSD (n = 12) enrolled in an 8-week program of MBCT classes (2 h each) that incorporated meditation, yoga, and mood regulation strategies. Participants were pregnant (n = 12), planning pregnancy (n = 11), or up to 1-year postpartum (n = 16). Participants were self-referred and most had subthreshold mood symptoms. Assessments of depression, (hypo)mania, and anxiety were obtained by interview and self-report at baseline, post-treatment and at 1- and 6-month post-treatment. Women with a history of MDD were more likely to complete the classes than women with BSD. Of 32 women who completed the classes, 7 (21.9 %) had a major depressive episode during the 6-month post-treatment follow-up. On average, participants with MDD reported improvements in depression from pre- to post-treatment. Mood improvement was not observed in the BSD group. In the full sample, improvements in depression symptoms across time points were associated with increasing mindful tendency scores. This study was limited by its uncontrolled design, heterogeneous sample, and questionnaire-based assessment of mindfulness skills. MBCT may be an important component of care for perinatal women with histories of major depression. Its applicability to perinatal women with BSD is unclear.

Comparable studies

Other non-randomized and open-label trials on depression, most cited first.

Study Year Design Participants
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Patients with moderate-to-severe, unipolar, treatment-resistant major depression 2016 Open-label feasibility trial n = 12
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression 2017 Open-label trial n = 20
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression Patients with recurrent depression 2015 Open-label trial n = 17

Citations in the library

Cited by 13

and 8 more in the library

Cites 13

and 8 more in the library

Explore topics